Gossamer Bio, Inc. registered up to 1,697,363 common shares issuable upon exercise of warrants issued in the June 4, 2026 early settlement of its 5.00% Convertible Senior Notes due 2027; the company will receive no sale proceeds.
GOSS · Gossamer Bio, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Gossamer Bio submitted its first Seralutinib NDA to the FDA in September 2026; cash, cash equivalents and marketable securities totaled $51.2 million as of September 30, 2026, and quarterly net loss was $48.1 million.
Gossamer Bio, Inc. reacquired worldwide seralutinib rights from Chiesi in July 2026 and submitted an NDA for PAH in September 2026. It had $51.2 million in cash, cash equivalents and marketable securities as of September 30, 2026.
Gossamer Bio stockholders approved, at an October 27, 2026 special meeting, issuing common stock under the August 20, 2026 Securities Purchase Agreement that would exceed 20% of outstanding shares. Votes: 2,808,000 for, 37,814 against, 29,441 abstaining.
On September 25, 2026, Gossamer Bio received Nasdaq notice that it regained compliance with the minimum bid price requirement, closing the matter. The company effected a 1-for-80 reverse stock split on September 10, 2026, and split-adjusted trading began on September 11, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 27, 2026TL;DR. Gossamer announced a clear regulatory path for its planned September 2026 NDA submission for seralutinib in PAH after FDA characterized efficacy concerns as review issues rather than filing issues, reacquired worldwide rights from Chiesi in exchange for a capped royalty and milestones, and completed a convertible note exchange that reduced debt by approximately $115.9 million, leaving approximately $57 million in cash as of June 30, 2026.
- + FDA Pre-NDA feedback frames PROSERA efficacy concerns as review issues rather than filing issues, clearing a path to September 2026 NDA submission and potential Q3 2027 approval decision.
- + Gossamer reacquired worldwide rights to seralutinib from Chiesi with no upfront cash payment and received a $5 million payment from Chiesi, retaining the substantial majority of global economics.
- + Convertible note exchange reduced aggregate debt principal by approximately $115.9 million and lowered outstanding 2027 Notes to approximately $18.9 million.
- − FDA has not yet accepted the planned NDA for filing or completed substantive review, and approvability remains uncertain.
- − Company had only approximately $57 million in cash as of June 30, 2026, which may be insufficient to fund a full commercial launch without additional capital.
- − Future performance is entirely dependent on the success of seralutinib, creating concentration risk.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, Cash Equivalents and Marketable Securities | $51.2M | as of September 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GOSS
this stock
Gossamer Bio, Inc.
|
$68.69M | — | -57.7% | — | 21.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 36
Gossamer Bio, Inc. registered up to 1,697,363 common shares issuable upon exercise of warrants issued in the June 4, 2026 early settlement of its 5.00% Convertible Senior Notes due 2027; the company will receive no sale proceeds.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GOSS | -0.1% | +18.7% | -29.1% | +8.2% | -95.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +5.4% | +25.0% | -23.5% | +13.5% | -100.5% |